Fridman R - Search Results

1

Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.

Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E. Schmalfeldt B, et al. Among authors: fridman r. Clin Cancer Res. 2001 Aug;7(8):2396-404. Clin Cancer Res. 2001. PMID: 11489818

2

Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.

Lengyel E, Schmalfeldt B, Konik E, Späthe K, Härting K, Fenn A, Berger U, Fridman R, Schmitt M, Prechtel D, Kuhn W. Lengyel E, et al. Among authors: fridman r. Gynecol Oncol. 2001 Aug;82(2):291-8. doi: 10.1006/gyno.2001.6243. Gynecol Oncol. 2001. PMID: 11531282

3

Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia.

Upadhyay J, Shekarriz B, Nemeth JA, Dong Z, Cummings GD, Fridman R, Sakr W, Grignon DJ, Cher ML. Upadhyay J, et al. Among authors: fridman r. Clin Cancer Res. 1999 Dec;5(12):4105-10. Clin Cancer Res. 1999. PMID: 10632347

4

Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade.

Bianco FJ Jr, Gervasi DC, Tiguert R, Grignon DJ, Pontes JE, Crissman JD, Fridman R, Wood DP Jr. Bianco FJ Jr, et al. Among authors: fridman r. Clin Cancer Res. 1998 Dec;4(12):3011-6. Clin Cancer Res. 1998. PMID: 9865914

5

Antimetastatic activity of a novel mechanism-based gelatinase inhibitor.

Krüger A, Arlt MJ, Gerg M, Kopitz C, Bernardo MM, Chang M, Mobashery S, Fridman R. Krüger A, et al. Among authors: fridman r. Cancer Res. 2005 May 1;65(9):3523-6. doi: 10.1158/0008-5472.CAN-04-3570. Cancer Res. 2005. PMID: 15867341

6

Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer.

Lubbe WJ, Zhou ZY, Fu W, Zuzga D, Schulz S, Fridman R, Muschel RJ, Waldman SA, Pitari GM. Lubbe WJ, et al. Among authors: fridman r. Clin Cancer Res. 2006 Mar 15;12(6):1876-82. doi: 10.1158/1078-0432.CCR-05-2686. Clin Cancer Res. 2006. PMID: 16551873

7

High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer.

Grignon DJ, Sakr W, Toth M, Ravery V, Angulo J, Shamsa F, Pontes JE, Crissman JC, Fridman R. Grignon DJ, et al. Among authors: fridman r. Cancer Res. 1996 Apr 1;56(7):1654-9. Cancer Res. 1996. PMID: 8603416

8

Density-dependent regulation of cell-surface association of matrix metalloproteinase-2 (MMP-2) in breast-carcinoma cells.

Menashi S, Dehem M, Souliac I, Legrand Y, Fridman R. Menashi S, et al. Among authors: fridman r. Int J Cancer. 1998 Jan 19;75(2):259-65. doi: 10.1002/(sici)1097-0215(19980119)75:2<259::aid-ijc15>3.0.co;2-8. Int J Cancer. 1998. PMID: 9462717

9

Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2).

Fridman R, Toth M, Peña D, Mobashery S. Fridman R, et al. Cancer Res. 1995 Jun 15;55(12):2548-55. Cancer Res. 1995. PMID: 7780967

10

Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells.

Dong Z, Nemeth JA, Cher ML, Palmer KC, Bright RC, Fridman R. Dong Z, et al. Among authors: fridman r. Int J Cancer. 2001 Aug 15;93(4):507-15. doi: 10.1002/ijc.1358. Int J Cancer. 2001. PMID: 11477554

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

198 results

Search Page

Filters